Glenmark receives ANDA approval for Clindamycin Phosphate Gel
According to IQVIA sales data for the 12 month period ending December 2020, the Cleocin T Gel, 1% market achieved annual sales of approximately $73.8 million.
According to IQVIA sales data for the 12 month period ending December 2020, the Cleocin T Gel, 1% market achieved annual sales of approximately $73.8 million.
Be One is a 100% Ayurvedic health and wellness supplement.
Indian Chemical News, an online news media covering Pharma, Chemical and Petrochemical sector is organizing an E-conference on “India's Pharma Industry Outlook 2021” on 12th February, 2021 from 3:00 PM – 4:30 PM.
The Department has been working continuously to ensure a stable long-term policy environment and reduce the compliance burden on the Industry.
The company posted net profit of Rs.7.61 crores for the period ended December 31, 2019.
The company posted net loss of Rs. 55.51 crores for the period ended December 31, 2019.
The company posted net profit of Rs.62.17 crores for the period ended December 31, 2019.
Tavaborole Topical Solution, 5%, is an oxaborole antifungal.
The company posted net profit of Rs.203.38 crores for the period ended December 31, 2019.
The DREAM-ND Phase III trial has now enrolled 588 CKD patients not-on-dialysis.
The company's business in India geography posted strong growth during the quarter as it grew by 20% on a y-o-y basis and registered revenues of Rs. 1,643 crore.
The company has posted net profit of Rs.397.06 crores for the 9 months period ended December 31, 2020.
The company posted net loss of Rs. 661.16 crores for the period ended December 31, 2019.
WACKER and Helixmith plan to strategically collaborate on the production of a pDNA gene therapy developed by Helixmith for the treatment of diabetic peripheral neuropathy (DPN).
This partnership is in line with the strategic focus of DKSH Business Unit Technology to solidify its position as a leading integrated solutions provider for the scientific Instrumentation market
The company has posted net profit of Rs.19.8 crores for the period ended December 31, 2020 as against net loss of Rs. 569.7 crores for the period ended December 31, 2019.
The company has reported total income of Rs.25699.68 crores during the 9 months period ended December 31, 2020.
The company has reported total income of Rs.14759 crores during the 9 months period ended December 31, 2020.
The company has concluded our acquisition of Richcore Lifesciences on 20th Jan 2021.
Lonza maintained business continuity during the COVID-19 pandemic with minimal impacts to operations and supply throughout 2020.
Subscribe To Our Newsletter & Stay Updated